Literature DB >> 15073969

Cholesterol-lowering drugs and antidepressants--a study of prescription symmetry.

G Lindberg1, J Hallas.   

Abstract

The subject of this study was to investigate the relationship between prescription of cholesterol-lowering drugs and depression. We used prescription of antidepressants as a proxy for depression and analysed the prescription order for cholesterol-lowering and antidepressant drugs. The ratio of persons with antidepressants prescribed second and first translates directly into a rate ratio (RR) associating cholesterol-lowering drugs use with antidepressants. The crude RRs were then adjusted for trends in sales of the drugs over the study period. All residents of Funen, Denmark, who started the two therapies during the period 1 April 1991 through 31 December 1995 were included in the study cohort. Of 184 individuals included in the analysis, 105 started antidepressant first and 79 second, giving a crude RR of 0.75. However, the sales of cholesterol-lowering drugs increased more than the sales of antidepressants. Accordingly, the adjusted RR was higher than the crude, 0.90 (95% confidence interval 0.68 to 1.22). Among three tested cholesterol-lowering drug classes, only simvastatin showed an adjusted RR above unity (1.59, 95% confidence interval 1.08 to 2.45). The hypothesis that the use of cholesterol-lowering drugs has an adverse effect on mood is not supported by the present study. Confounding by indication might explain the apparent association between use of simvastatin and antidepressants. Copyright 1998 John Wiley & Sons, Ltd.

Entities:  

Year:  1998        PMID: 15073969     DOI: 10.1002/(SICI)1099-1557(199811/12)7:6<399::AID-PDS385>3.0.CO;2-C

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

1.  Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia.

Authors:  Izyan A Wahab; Nicole L Pratt; Lisa M Kalisch; Elizabeth E Roughead
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

Review 2.  Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies.

Authors:  Edward Chia-Cheng Lai; Nicole Pratt; Cheng-Yang Hsieh; Swu-Jane Lin; Anton Pottegård; Elizabeth E Roughead; Yea-Huei Kao Yang; Jesper Hallas
Journal:  Eur J Epidemiol       Date:  2017-07-11       Impact factor: 8.082

Review 3.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

4.  Prescribing cascades in community-dwelling adults: A systematic review.

Authors:  Ann S Doherty; Faiza Shahid; Frank Moriarty; Fiona Boland; Barbara Clyne; Tobias Dreischulte; Tom Fahey; Seán P Kennelly; Emma Wallace
Journal:  Pharmacol Res Perspect       Date:  2022-10

Review 5.  Assessment of Medication Safety Using Only Dispensing Data.

Authors:  Nicole Pratt; Elizabeth Roughead
Journal:  Curr Epidemiol Rep       Date:  2018-09-28

6.  Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies.

Authors:  Riccardo De Giorgi; Nicola Rizzo Pesci; Alice Quinton; Franco De Crescenzo; Philip J Cowen; Catherine J Harmer
Journal:  Front Psychiatry       Date:  2021-07-27       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.